Legend Biotech Financial Statements
NASDAQ: LEGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Legend Biotech revenue and earnings
In fiscal 2025, Legend Biotech generated $1.03 billion in revenue, up 64.0% from fiscal 2024, its 4th consecutive year of revenue growth. Legend Biotech reported a net loss of $296.8 million, compared with a loss of $177.0 million a year earlier. Gross margin was 61.4% (down from 65.5%) and operating margin -13.3%.
Diluted earnings per share came in at -$0.81. Over the last 5 fiscal years, LEGN's revenue has grown at a 68.8% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
Legend Biotech income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.03B | 627.24M | 285.14M | 117.00M | 68.83M | 75.00M | 59.98M | 49.13M |
| Revenue growth (YoY) | +64.04% | +119.97% | +143.70% | +70.00% | -8.23% | +25.04% | +22.08% | — |
| Cost of Revenue | 397.10M | 216.40M | 144.20M | 65.36M | 0 | 0 | — | — |
| Gross Profit | 631.80M | 410.84M | 140.94M | 51.64M | 68.83M | 75.00M | — | — |
| Operating Expenses | 768.30M | 720.34M | 669.04M | — | — | — | — | — |
| Research & Development | 414.70M | 413.50M | 382.20M | 335.65M | 313.35M | 232.16M | 161.94M | 60.64M |
| Operating Income | -136.50M | -309.50M | -528.10M | — | — | — | — | — |
| Interest Expense | 21.40M | 21.60M | 21.80M | 10.80M | 900.00K | 4.21M | 223.00K | 82.00K |
| Other Income (Expense) | -164.80M | 111.80M | -24.80M | 1.34M | 317.00K | 113.00K | 1.06M | — |
| Pretax Income | -282.60M | -158.10M | -520.20M | -445.72M | -407.20M | -308.29M | -127.32M | -1.62M |
| Income Tax | 14.20M | 18.90M | -1.90M | 625.00K | -3.61M | -41.91M | -25.73M | 1.17M |
| Net Income | -296.80M | -177.03M | -518.25M | -446.35M | -403.58M | -266.37M | -101.59M | -2.78M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — |
| EPS (Basic) | -0.81 | -0.48 | -1.47 | -1.40 | -1.43 | -1.13 | -0.51 | -0.01 |
| EPS (Diluted) | -0.81 | -0.48 | -1.47 | -1.40 | -1.43 | -1.13 | -0.51 | -0.01 |
| Shares Outstanding (Basic) | 368.64M | 365.70M | 352.17M | 318.08M | 281.70M | 236.31M | 200.00M | 200.00M |
| Shares Outstanding (Diluted) | 368.64M | 365.70M | 352.17M | 318.08M | — | — | — | — |
| Gross Margin | 61.41% | 65.50% | 49.43% | 44.14% | 100.00% | 100.00% | — | — |
| Operating Margin | -13.27% | -49.34% | -185.21% | — | — | — | — | — |
| Net Margin | -28.85% | -28.22% | -181.75% | -381.48% | -586.38% | -355.16% | -169.37% | -5.67% |
This table shows 8 annual periods of Legend Biotech's income statement, from FY 2025 back to FY 2018, across 18 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow LEGN's reporting calendar. What is a income statement?